EpiCypher CUTANA meCUT&RUN and Multiomic CUT&RUN DNA methylation sequencing assays

EpiCypher has announced CUTANA meCUT&RUN and Multiomic CUT&RUN — two novel DNA methylation sequencing technologies designed to advance the frontiers of genomic research and drug discovery.

DNA methylation is a critical epigenetic mechanism that regulates gene expression, genomic imprinting and cell identity. Bisulfite sequencing, the traditional gold-standard method for mapping 5-methylcytosine (5mC), suffers from limitations including DNA degradation, excessive sequencing costs and high cell input requirements, making it difficult to integrate with other epigenomic workflows.

CUTANA meCUT&RUN directly extends EpiCypher’s CUT&RUN core platform to DNA methylation by leveraging a novel methyl-DNA binding fusion protein that enriches 5mC with high specificity. With base-pair resolution, this approach is said to be capable of detecting >80% of methyl-CpGs captured by whole-genome approaches while using >20 times less sequencing, for scalable, low-cost DNA methylation analysis. It offers streamlined workflows compatible with cell lines, primary cells and patient-derived samples.

Building on this innovation, the CUTANA Multiomic CUT&RUN assay offers researchers the ability to co-profile chromatin features (eg, histone modifications or DNA-binding proteins) alongside DNA methylation. Such simultaneous capture uncovers the dynamic relationship between two fundamental layers of epigenetic regulation — unlocking critical insights for foundational research and translational drug discovery.

The two products are designed to deliver genome-wide insights using a targeted, cost-efficient approach, bringing comprehensive methylation analysis within reach for a broader range of researchers and applications. They are now available to academic, biotech and pharmaceutical researchers pursuing discovery in cancer biology, neuroscience, immunology, aging and beyond.